NewAmsterdam Pharma (NAMS) Expected to Post Quarterly Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is projected to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect NewAmsterdam Pharma to announce earnings of ($0.4726) per share and revenue of $1.8770 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. On average, analysts expect NewAmsterdam Pharma to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NewAmsterdam Pharma Trading Down 1.1%

Shares of NASDAQ:NAMS opened at $27.49 on Tuesday. NewAmsterdam Pharma has a 12 month low of $21.23 and a 12 month high of $42.21. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -15.36 and a beta of 0.08. The firm’s 50-day moving average is $32.00 and its 200 day moving average is $32.62.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at $738,870.02. This represents a 81.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 210,000 shares of company stock worth $6,713,550 in the last ninety days. 12.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its stake in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. Empowered Funds LLC bought a new position in NewAmsterdam Pharma in the fourth quarter worth about $85,000. Persistent Asset Partners Ltd purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at about $138,000. The Manufacturers Life Insurance Company lifted its position in shares of NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after buying an additional 544 shares during the last quarter. Finally, Guggenheim Capital LLC bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at about $224,000. 89.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on NAMS shares. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price target on the stock. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Finally, Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $49.42.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.